ASO Visual Abstract: Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group

2021 ◽  
Author(s):  
Candice A. M. Sauder ◽  
Qian Li ◽  
Richard J. Bold ◽  
Kathryn J. Ruddy ◽  
Theresa H. M. Keegan
Keyword(s):  
Breast Cancer ◽  
Sociodemographic Characteristics ◽  
Age Group ◽  
Secondary Breast Cancer

scholarly journals A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yujing Xin ◽  
Xinyuan Zhang ◽  
Yi Yang ◽  
Yi Chen ◽  
Yanan Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
False Negative ◽  
Final Analysis ◽  
Age Group ◽  
Surgical Biopsy ◽  
True Negative ◽  
Diagnostic Efficacy ◽  
Negative Results ◽  
Informed Consent Form ◽  
Magnetic Resonance Imaging Mri

AbstractThis study is the first multi-center non-inferiority study that aims to critically evaluate the effectiveness of HHUS/ABUS in China breast cancer detection. This was a multicenter hospital-based study. Five hospitals participated in this study. Women (30–69 years old) with defined criteria were invited for breast examination by HHUS, ABUS or/and mammography. For BI-RADS category 3, an additional magnetic resonance imaging (MRI) test was provided to distinguish the true negative results from false negative results. For women classified as BI-RADS category 4 or 5, either core aspiration biopsy or surgical biopsy was done to confirm the diagnosis. Between February 2016 and March 2017, 2844 women signed the informed consent form, and 1947 of them involved in final analysis (680 were 30 to 39 years old, 1267 were 40 to 69 years old).For all participants, ABUS sensitivity (91.81%) compared with HHUS sensitivity (94.70%) with non-inferior Z tests, P = 0.015. In the 40–69 age group, non-inferior Z tests showed that ABUS sensitivity (93.01%) was non-inferior to MG sensitivity (86.02%) with P < 0.001 and HHUS sensitivity (95.44%) was non-inferior to MG sensitivity (86.02%) with P < 0.001. Sensitivity of ABUS and HHUS are all superior to that of MG with P < 0.001 by superior test.For all participants, ABUS specificity (92.89%) was non-inferior to HHUS specificity (89.36%) with P < 0.001. Superiority test show that specificity of ABUS was superior to that of HHUS with P < 0.001. In the 40–69 age group, ABUS specificity (92.86%) was non-inferior to MG specificity (91.68%) with P < 0.001 and HHUS specificity (89.55%) was non-inferior to MG specificity (91.68%) with P < 0.001. ABUS is not superior to MG with P = 0.114 by superior test. The sensitivity of ABUS/HHUS is superior to that of MG. The specificity of ABUS/HHUS is non-inferior to that of MG. In China, for an experienced US radiologist, both HHUS and ABUS have better diagnostic efficacy than MG in symptomatic individuals.

Primary tumor dependent inhibition of tumor growth, angiogenesis, and perfusion of secondary breast cancer in bone

2011 ◽  
Vol 29 (8) ◽  
pp. 1251-1258 ◽  
Author(s):  
Christian Schaefer ◽  
Malte Schroeder ◽  
Ina Fuhrhop ◽  
Lennart Viezens ◽  
Jasmin Otten ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Primary Tumor ◽  
Dependent Inhibition ◽  
Inhibition Of Tumor Growth ◽  
Secondary Breast Cancer

scholarly journals Secondary breast cancer after Hodgkin lymphoma: a case report and literature review

2018 ◽  
Vol 12 ◽  
Author(s):  
Joaira Bakkach ◽  
Mohamed Mansouri ◽  
Ali Loudiyi ◽  
Naima Ghailani Nourouti ◽  
Amina Barakat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Literature Review ◽  
Hodgkin Lymphoma ◽  
Secondary Breast Cancer

scholarly journals Terapia Física Descongestiva no tratamento do linfedema secundário ao câncer de mama: uma revisão sistemática / Decongestive Physical Therapy in the treatment of secondary breast cancer lymphedema: a systematic review

2020 ◽  
Vol 14 (53) ◽  
pp. 330-340
Author(s):  
Marilange Araújo de Almeida Souza ◽  
Aline Marques Piloto ◽  
Rosana Porto Cirqueira
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Physical Therapy ◽  
Cáncer De Mama ◽  
Secondary Breast Cancer ◽  
De Medicina

Resumo: O linfedema secundário é disfunção linfática crônica caraterizado como uma consequência do processo cirúrgico do câncer de mama que pode ser tratado por procedimento cirúrgico ou conservador. O objetivo foi realizar uma revisão sistemática da literatura sobre a utilização da terapia física descongestiva no tratamento do linfedema secundário e seus efeitos na redução do linfedema. Trata-se de uma revisão sistemática de literatura com artigos publicados nas bases de dados do Scientific Eletronic Library Online, Biblioteca Nacional de Medicina, Literatura Latino-Americana e Google Acadêmico, nos anos de 2010 a 2019. Foram selecionados 10 estudos que demonstraram efeitos positivos da terapia física descongestiva no tratamento do linfedema secundário e seus efeitos benefícios na redução do linfedema. A revisão sistemática comprovou os terapia física descongestiva é uma aliada no tratamento conservador do linfedema secundário de câncer de m

scholarly journals A retrospective study of colorectal carcinoma in central India

2017 ◽  
Vol 4 (3) ◽  
pp. 977
Author(s):  
Suresh Clement H. ◽  
S. Madhu Babu ◽  
Samir Ahmad ◽  
Harsha Omkar M.
Keyword(s):  
Breast Cancer ◽  
Central India ◽  
Cross Sectional Study ◽  
Reproductive Age ◽  
Age Group ◽  
Cross Sectional ◽  
Outer Quadrant ◽  
The World ◽  
Menstruating Women ◽  
Epidemiological Profile

Background: Inner lining of lobules or ducts of milk of breast tissue is the origin of the breast cancer. Among females, it constitutes 10.4% of cancer cases incidence all over the world. It thus is the fifth leading cause of mortality all over the world. As known, it is more common in females than males. The objective of this study was to study the clinical and epidemiological profile of breast cancer patients.Methods: A hospital based cross sectional study was carried out for a period of two and half years at M. G. M. Hospital, Warangal. Both males and females of 30 years and above were included in the study. Total number of carcinoma cases admitted during 2005 to 2007 for a period of two and half years were 1,428. Total number of carcinoma breast cases admitted during 2005 to 2007 for a period of two and half years were 242.Results: Maximum cases i.e. 44.6% belonged to stage III of breast cancer. Maximum cases were seen among Hindus i.e. 76.4%. As expected, only one case was reported by males which constituted only 0.42%. Highest number of cases i.e. 99 (40.9%) were reported during the age group of 40-50 years. Multi para women constituted more number of cases in 78.8%. Maximum number of cases of breast cancer i.e. 41.6% occurred among menstruating women. Most commonly affected quadrant was upper outer in 55.1% of cases. The most common type was Schirrous carcinoma in 39.6% of cases.Conclusions: Upper outer quadrant was most commonly affected. This indicates that the women in the reproductive age group should be directed to examine their breast daily with specific attention to upper outer quadrant.

scholarly journals Immunohistochemistry profile and its relation with prognosis in locally advanced breast cancer

2019 ◽  
Vol 6 (12) ◽  
pp. 4507
Author(s):  
Naseef Kannanavil ◽  
Nabeel Thommil Padinjarenalakath ◽  
Ahsan Vilayapoyilil ◽  
Abidali Karatparambil
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Locally Advanced ◽  
Radical Mastectomy ◽  
Response To Therapy ◽  
Advanced Breast ◽  
Age Group ◽  
Modified Radical Mastectomy ◽  
Number Of Patients ◽  
Related Mortality

Background: Breast cancer is one of the most common malignancy and leading cause of cancer related deaths in women worldwide. Immunohistochemistry (IHC) is done to characterize intracellular proteins or cell-surface antigens and is used to assess tumour subtypes, confirm diagnosis, predict prognosis and response to therapy. The aim of the present study was to evaluate the relationship of IHC profile- ER, PR and HER2 neu and prognosis of patients who underwent modified radical mastectomy for locally advanced breast cancer.Methods: A retrospective cohort study was conducted at MES Medical College Hospital from October 2015 to November 2017 in patients who underwent modified radical mastectomy for locally advanced breast carcinoma. A total of 65 women were enrolled in the study. 5 years survival was taken as the prognostic indicator.Results: Majority of the patients belong to the age group of 40-49 years with 40% patients followed by 33.84% patients in the age group of 50-59 years. Maximum number of patients was found in 2B stage of tumour. Maximum patients belonged to the ER/PR+, HER2- subgroup (27), followed by triple negative (ER/PR-, HER2) subgroup (16). There was no disease related mortality in ER/PR+, HER2+ and ER/PR+, HER2- subgroups. There were 1 and 2 disease related mortality in ER/PR-, HER2+ and triple negative subgroups respectively.Conclusions: In the present study the worst prognosis was observed in triple negative (ER/PR-,HER2-) IHC subgroup followed by the HER2 enriched (ER/PR-, HER2+) subgroup. 

scholarly journals Osteoporosis OSTEOPOROSIS –IN OLD AGE AND GERIATRICS

2020 ◽  
Vol 8 (02) ◽  
Author(s):  
Reena mishra Reena
Keyword(s):  
Breast Cancer ◽  
Bone Loss ◽  
Old Age ◽  
Published Data ◽  
Age Group ◽  
Large Drop ◽  
Heart Attacks ◽  
Health Initiative ◽  
In The Beginning ◽  
Whi Study

In the beginning, that is from the 1960's, when a link between menopause and osteoporosis was first identified; estrogen treatment was the standard for preventing bone loss, however there was no fracture data, even though it was thought to be effective. This continued until the Women's Health Initiative (WHI) study in 2001 that published data on 6 years of treatment with hormone therapy that showed an increase in heart attacks and breast cancer. Even though the risks were small, 1 per 1500 users annually, patients were worried and there was a large drop off in estrogen use. In later analyses the WHI study showed that estrogen reduced fractures and actually prevented heart attacks in the 50-60 year age group. Estrogen alone appeared to be safer to use than estrogen + the progestin medroxyprogesterone acetate and actually reduced breast cancer.  

Sign in / Sign up

Export Citation Format

Share Document